Legacy Advisors LLC Invests $209,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Legacy Advisors LLC purchased a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 514 shares of the pharmaceutical company’s stock, valued at approximately $209,000.

Several other large investors also recently bought and sold shares of the business. Arlington Trust Co LLC increased its position in Vertex Pharmaceuticals by 97.1% during the 4th quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 33 shares during the period. Fortitude Family Office LLC purchased a new stake in Vertex Pharmaceuticals during the 4th quarter worth approximately $30,000. Baystate Wealth Management LLC lifted its stake in Vertex Pharmaceuticals by 49.0% during the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after acquiring an additional 25 shares during the period. Quest Partners LLC acquired a new stake in Vertex Pharmaceuticals during the 4th quarter valued at approximately $33,000. Finally, NBC Securities Inc. acquired a new position in shares of Vertex Pharmaceuticals in the 3rd quarter valued at $34,000. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

Shares of Vertex Pharmaceuticals stock traded down $2.93 during trading on Thursday, reaching $438.20. 161,619 shares of the company’s stock were exchanged, compared to its average volume of 1,203,595. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.29 and a current ratio of 3.50. Vertex Pharmaceuticals Incorporated has a 1-year low of $320.01 and a 1-year high of $457.66. The company has a market cap of $113.08 billion, a P/E ratio of 28.63, a PEG ratio of 2.29 and a beta of 0.39. The firm’s 50-day moving average price is $415.61 and its 200 day moving average price is $408.36.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Free Report) last issued its earnings results on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.66 by $1.10. Vertex Pharmaceuticals had a return on equity of 23.08% and a net margin of 39.46%. The business had revenue of $2.69 billion during the quarter, compared to analysts’ expectations of $2.58 billion. During the same quarter in the prior year, the firm earned $2.67 EPS. The business’s revenue for the quarter was up 13.3% compared to the same quarter last year. As a group, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on VRTX shares. Barclays upped their target price on shares of Vertex Pharmaceuticals from $446.00 to $472.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Guggenheim increased their price target on shares of Vertex Pharmaceuticals from $445.00 to $450.00 and gave the stock a “buy” rating in a research report on Thursday, April 18th. JPMorgan Chase & Co. raised their target price on shares of Vertex Pharmaceuticals from $390.00 to $438.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. StockNews.com lowered shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday. Finally, Royal Bank of Canada raised their target price on Vertex Pharmaceuticals from $417.00 to $424.00 and gave the company a “sector perform” rating in a report on Tuesday, May 7th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $432.18.

Check Out Our Latest Stock Report on VRTX

Insider Buying and Selling at Vertex Pharmaceuticals

In related news, CEO Reshma Kewalramani sold 1,565 shares of the company’s stock in a transaction dated Friday, May 24th. The stock was sold at an average price of $457.00, for a total transaction of $715,205.00. Following the sale, the chief executive officer now owns 121,374 shares in the company, valued at approximately $55,467,918. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Vertex Pharmaceuticals news, CEO Reshma Kewalramani sold 1,565 shares of the stock in a transaction that occurred on Friday, May 24th. The stock was sold at an average price of $457.00, for a total value of $715,205.00. Following the transaction, the chief executive officer now owns 121,374 shares in the company, valued at $55,467,918. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Bruce I. Sachs sold 7,073 shares of the stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $448.00, for a total value of $3,168,704.00. Following the completion of the transaction, the director now owns 40,000 shares in the company, valued at approximately $17,920,000. The disclosure for this sale can be found here. Corporate insiders own 0.20% of the company’s stock.

About Vertex Pharmaceuticals

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Recommended Stories

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.